We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
- Authors
Yao, Liqin; Jia, Gang; Lu, Lingeng; Ma, Wenxue
- Abstract
Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited. Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT.
- Subjects
CANCER chemotherapy; BREAST cancer patients; CANCER cells; HLA histocompatibility antigens; LYMPHOCYTES; MACROPHAGES
- Publication
Current Oncology, 2022, Vol 29, Issue 7, p4902
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol29070389